Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLNR | O43193 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243510 | 0.85 | HRH3 (0.46) | USP2HTTGAAALDH1A1KDM4E | |
| SCHEMBL1244033 | 0.84 | USP2 (0.52) | USP2HTTGAAPKMALDH1A1 | |
| SCHEMBL1243667 | 0.82 | HTR7 (0.46) | USP2HTTGAAALDH1A1KDM4E | |
| SCHEMBL1244022 | 0.80 | USP2 (0.48) | USP2HTTGAAPKMALDH1A1 | |
| SCHEMBL1242833 | 0.77 | ALDH1A1 (0.52) | USP2ALDH1A1LMNAMAPK1TSHR | |
| SCHEMBL1243397 | 0.74 | HTR7 (0.43) | USP2HTTGAAPKMALDH1A1 | |
| SCHEMBL1243531 | 0.74 | MLNR (0.50) | MLNRUSP2HTTGAAPKM | |
| Oxalic Acid SCHEMBL1242817 | 0.74 | ALDH1A1 (0.53) | USP2HTTGAAALDH1A1KDM4E | |
| SCHEMBL1241257 | 0.73 | HTR2C (0.61) | USP2GAAPKMHTR2CHTR2B | |
| SCHEMBL25591709 | 0.72 | SMN1; SMN2 (0.45) | MLNRGAAALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1753725-B1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI SA (FR) | 2013-02-27 | — | — | EP | claimed |
| US-8273733-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2012-09-25 | — | — | US | claimed |
| US-20110028475-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2011-02-03 | — | — | US | claimed |
| US-7833999-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | claimed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | claimed |
| EP-1753725-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-02-21 | — | — | EP | claimed |
| WO-2005118547-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-12-15 | — | — | WO | claimed |
| US-8524700-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-8524700-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| US-8524700-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI (FR) | 2013-09-03 | — | — | US | disclosed |
| EP-1753725-B1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI SA (FR) | 2013-02-27 | — | — | EP | disclosed |
| EP-1753725-B1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI SA (FR) | 2013-02-27 | — | — | EP | disclosed |
| US-20120323003-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI (FR) | 2012-12-20 | — | — | US | disclosed |
| US-7833999-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-7833999-B2 | Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics | SANOFI-AVENTIS (FR) | 2010-11-16 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2007-05-10 | — | — | US | disclosed |
| EP-1753725-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005118547-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323003-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, HTR2B, KCNQ2 | MLNR 3133/4885USP2 2521/4885HTT 309/4885 |
| US-20070105834-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, SLC6A2, KCNQ2 | MLNR 3636/4885USP2 2792/4885HTT 176/4885 |
| US-20110028475-A1 | TETRAHYDROISOQUINOLINE SULFONAMIDE DERIVATIVES, THE PREPARATION THEREOF, AND THE USE OF THE SAME IN THERAPEUTICS | BACE1, HTR2B, KCNQ2 | MLNR 3133/4885USP2 2521/4885HTT 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.